CXCR4 as biomarker for radioresistant cancer stem cells
- PMID: 24650104
- DOI: 10.3109/09553002.2014.906766
CXCR4 as biomarker for radioresistant cancer stem cells
Abstract
Purpose: Radioresistance of cancer cells remains a fundamental barrier for maximum efficient radiotherapy. Tumor heterogeneity and the existence of distinct cell subpopulations exhibiting different genotypes and biological behaviors raise difficulties to eradicate all tumorigenic cells. Recent evidence indicates that a distinct population of tumor cells, called cancer stem cells (CSC), is involved in tumor initiation and recurrence and is a putative cause of tumor radioresistance. There is an urgent need to identify the intrinsic molecular mechanisms regulating the generation and maintenance of resistance to radiotherapy, especially within the CSC subset. The chemokine C-X-C motif receptor 4 (CXCR4) has been found to be a prognostic marker in various types of cancer, being involved in chemotaxis, stemness and drug resistance. The interaction of CXCR4 with its ligand, the chemokine C-X-C motif ligand 12 (CXCL12), plays an important role in modulating the tumor microenvironment, angiogenesis and CSC niche. Moreover, the therapeutic inhibition of the CXCR4/CXCL12 signaling pathway is sensitizing the malignant cells to conventional anti-cancer therapy.
Content: Within this review we are summarizing the role of the CXCR4/CXCL12 axis in the modulation of CSC properties, the regulation of the tumor microenvironment in response to irradiation, therapy resistance and tumor relapse.
Conclusion: In light of recent findings, the inhibition of the CXCR4/CXCL12 signaling pathway is a promising therapeutic option to refine radiotherapy.
Keywords: Radiotherapy; biomarker; cancer stem cells; radioresistance.
Similar articles
-
Hypoxia as a biomarker for radioresistant cancer stem cells.Int J Radiat Biol. 2014 Aug;90(8):636-52. doi: 10.3109/09553002.2014.916841. Epub 2014 Jun 25. Int J Radiat Biol. 2014. PMID: 24844374 Review.
-
Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.Toxicology. 2013 Dec 15;314(2-3):209-20. doi: 10.1016/j.tox.2013.10.003. Epub 2013 Oct 21. Toxicology. 2013. PMID: 24157575
-
SDF-1-CXCR4 axis: cell trafficking in the cancer stem cell niche of head and neck squamous cell carcinoma.Oncol Rep. 2013 Jun;29(6):2325-31. doi: 10.3892/or.2013.2380. Epub 2013 Apr 3. Oncol Rep. 2013. PMID: 23563306
-
Functional effects of SDF-1α on a CD44(+) CXCR4(+) squamous cell carcinoma cell line as a model for interactions in the cancer stem cell niche.Oncol Rep. 2013 Feb;29(2):579-84. doi: 10.3892/or.2012.2171. Epub 2012 Dec 10. Oncol Rep. 2013. PMID: 23232503
-
CXCR4 and cancer.Pathol Int. 2010 Jul;60(7):497-505. doi: 10.1111/j.1440-1827.2010.02548.x. Pathol Int. 2010. PMID: 20594270 Review.
Cited by
-
The therapeutic effect of traditional Chinese medicine on breast cancer through modulation of the Wnt/β-catenin signaling pathway.Front Pharmacol. 2024 May 9;15:1401979. doi: 10.3389/fphar.2024.1401979. eCollection 2024. Front Pharmacol. 2024. PMID: 38783943 Free PMC article. Review.
-
trans-IV restriction: a new configuration for metal bis-cyclam complexes as potent CXCR4 inhibitors.Dalton Trans. 2024 Mar 19;53(12):5616-5623. doi: 10.1039/d3dt01729j. Dalton Trans. 2024. PMID: 38439632 Free PMC article.
-
Downregulation of complement factor H attenuates the stemness of MDA‑MB‑231 breast cancer cells via modulation of the ERK and p38 signaling pathways.Oncol Lett. 2023 Oct 18;26(6):521. doi: 10.3892/ol.2023.14107. eCollection 2023 Dec. Oncol Lett. 2023. PMID: 37927420 Free PMC article.
-
Recruitment mechanisms and therapeutic implications of tumor-associated macrophages in the glioma microenvironment.Front Immunol. 2023 Apr 20;14:1067641. doi: 10.3389/fimmu.2023.1067641. eCollection 2023. Front Immunol. 2023. PMID: 37153567 Free PMC article. Review.
-
Inhibition of CXCR4 Enhances the Efficacy of Radiotherapy in Metastatic Prostate Cancer Models.Cancers (Basel). 2023 Feb 6;15(4):1021. doi: 10.3390/cancers15041021. Cancers (Basel). 2023. PMID: 36831366 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources